Browsing Tag
Stargardt disease
5 posts
How the GARDian3 trial could define the next commercial frontier in ophthalmic gene therapy
Discover how Ocugen, Inc.’s GARDian3 trial could redefine the commercial future of ophthalmic gene therapy and what investors should watch next.
Why VG801 could reshape endpoint strategy in inherited retinal disease development
VG801 shows early vision gains in Stargardt disease. Discover how VeonGen Therapeutics is redefining endpoints and regulatory strategy.
Stargardt disease pipeline shifts as Belite Bio clears enrollment risk for tinlarebant
Discover why Belite Bio’s DRAGON II enrollment milestone shifts Stargardt disease drug development and what it means for investors and regulators.
Belite Bio wins UK MHRA nod to file conditional marketing application for tinlarebant in Stargardt disease
Find out how Belite Bio gained UK MHRA backing to file a conditional marketing application for tinlarebant, advancing the first potential therapy for Stargardt disease.
Biogen to acquire Nightstar Therapeutics in a deal worth $800m to target retinal diseases
In a significant move within the biotech sector, Biogen, the US-based biotechnology giant, has announced its agreement to…